BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26980765)

  • 1. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).
    Tsuchihashi K; Okazaki S; Ohmura M; Ishikawa M; Sampetrean O; Onishi N; Wakimoto H; Yoshikawa M; Seishima R; Iwasaki Y; Morikawa T; Abe S; Takao A; Shimizu M; Masuko T; Nagane M; Furnari FB; Akiyama T; Suematsu M; Baba E; Akashi K; Saya H; Nagano O
    Cancer Res; 2016 May; 76(10):2954-63. PubMed ID: 26980765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
    Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
    Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells.
    Thomas AG; Sattler R; Tendyke K; Loiacono KA; Hansen H; Sahni V; Hashizume Y; Rojas C; Slusher BS
    PLoS One; 2015; 10(8):e0127785. PubMed ID: 26252954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
    Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Cassady K; Aboody KS
    Mol Cancer Res; 2016 Dec; 14(12):1229-1242. PubMed ID: 27658422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration.
    Wolf IM; Fan Z; Rauh M; Seufert S; Hore N; Buchfelder M; Savaskan NE; Eyüpoglu IY
    Sci Rep; 2014 Sep; 4():6226. PubMed ID: 25228443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autocrine glutamate signaling promotes glioma cell invasion.
    Lyons SA; Chung WJ; Weaver AK; Ogunrinu T; Sontheimer H
    Cancer Res; 2007 Oct; 67(19):9463-71. PubMed ID: 17909056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.
    Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W
    Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.
    Polewski MD; Reveron-Thornton RF; Cherryholmes GA; Marinov GK; Aboody KS
    Stem Cells Dev; 2017 Sep; 26(17):1236-1246. PubMed ID: 28610554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
    Sleire L; Skeie BS; Netland IA; Førde HE; Dodoo E; Selheim F; Leiss L; Heggdal JI; Pedersen PH; Wang J; Enger PØ
    Oncogene; 2015 Dec; 34(49):5951-9. PubMed ID: 25798841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrogen peroxide triggers an increase in cell surface expression of system x
    Chase LA; VerHeulen Kleyn M; Schiller N; King AG; Flores G; Engelsman SB; Bowles C; Smith SL; Robinson AE; Rothstein J
    Neurochem Int; 2020 Mar; 134():104648. PubMed ID: 31874187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.
    Linher-Melville K; Nashed MG; Ungard RG; Haftchenary S; Rosa DA; Gunning PT; Singh G
    PLoS One; 2016; 11(8):e0161202. PubMed ID: 27513743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial Glutamate Transporter-Mediated Plasticity: System x
    Dahlmanns M; Dahlmanns JK; Savaskan N; Steiner HH; Yakubov E
    Front Biosci (Landmark Ed); 2023 Mar; 28(3):57. PubMed ID: 37005761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
    Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
    Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species involved in the glutamate toxicity of C6 glioma cells via xc antiporter system.
    Mawatari K; Yasui Y; Sugitani K; Takadera T; Kato S
    Neuroscience; 1996 Jul; 73(1):201-8. PubMed ID: 8783242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
    Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
    Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.